Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Laser Therapy in the Isotretinoin-Induced Sacroiliitis

NCT: NCT07264153 · COMPLETED

NCT IDNCT07264153
StatusCOMPLETED
Start Date2025-11-24
Completion2026-06-11
SponsorUşak University (OTHER)
First posted
Last updated

Brief Summary

The clinical significance of this adverse effect lies in its impact on quality of life and the potential for misdiagnosis. The symptomatology can be severe enough to limit daily activities and may be mistakenly attributed to a primary rheumatic disease, leading to unnecessary long-term immunosuppressive therapy if the temporal link to isotretinoin is not identified. Therefore, a high index of suspicion is crucial for dermatologists, rheumatologists, and primary care physicians alike. Aim: To compare the effectiveness of High-Intensity Laser Therapy (HILT) in reducing pain intensity, in patients diagnosed with Isotretinoin-Induced Sacroiliitis.

Frequently Asked Questions

What is Laser Therapy in the Isotretinoin-Induced Sacroiliitis?

Laser Therapy in the Isotretinoin-Induced Sacroiliitis is a clinical trial registered under NCT07264153. Current status: COMPLETED.

What is the status of NCT07264153?

The current status of NCT07264153 (Laser Therapy in the Isotretinoin-Induced Sacroiliitis) is: COMPLETED.

When did Laser Therapy in the Isotretinoin-Induced Sacroiliitis start?

Laser Therapy in the Isotretinoin-Induced Sacroiliitis started on 2025-11-24.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.